Ruben Alvarez-Fernandez
Gijon, AS, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.
Journal: Frontiers in immunology
Published: September 13, 2023
Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker Subanalysis.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 21, 2022
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study).
Journal: Clinical lymphoma, myeloma & leukemia
Published: May 21, 2021
Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Journal: Journal for immunotherapy of cancer
Published: May 08, 2021
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.
Journal: Cancer medicine
Published: April 28, 2020
Survival outcomes of patients with extranodal natural-killer T-cell lymphoma: a prospective cohort study from the international T-cell Project.
Journal: The Lancet. Haematology
Published: August 29, 2019
Is there a role for the international prognostic index in follicular lymphoma?
Journal: Annals of hematology
Published: May 22, 2017
Hyperammonemic encephalopathy as the presenting feature of multiple myeloma
Journal: Medicina clinica
Published: July 11, 2016
Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.
Journal: Hematological oncology
Published: June 16, 2016
Serum ferritin as prognostic marker in classical Hodgkin lymphoma treated with ABVD-based therapy.
Journal: Leukemia & lymphoma
Published: April 11, 2015
Last Updated: 09/26/2026